… of patients suffering from prostate cancer. In this prevailing scenario, abiraterone acetate (AA)
has proved to be a boon for patients suffering from prostate cancer. AA selectively inhibits …

… progressing castration-resistant prostate cancer who had not received … abiraterone acetate
and prednisone would improve overall survival among patients with advanced prostate cancer…

… This final analysis confirms that abiraterone acetate significantly prolongs overall survival
in patients with metastatic castration-resistant prostate cancer who have progressed after …

… , and irreversible inhibitor of CYP17, abiraterone, 13,14 which … the antitumor activity of
abiraterone acetate, this phase I … the antitumor activity of abiraterone acetate administered at 1,000 …

… There was no evidence of a difference in metatasis-free survival when enzalutamide and
abiraterone acetate were administered concurrently compared with abiraterone acetate alone (…

… Hence, the term castration-resistant prostate cancer (CRPC) is … analyse the emerging role of
abiraterone acetate (AA), a … The key enzyme inhibited by abiraterone acetate (AA) is CYP17, …

… Abiraterone acetate plus prednisone significantly improves radiographic progression-free …
patients with metastatic castration-resistant prostate cancer compared with prednisone alone. …

… In this double-blind study, we randomly assigned 1088 patients to receive abiraterone acetate
(1000 mg) plus prednisone (5 mg twice daily) or placebo plus prednisone. The coprimary …

… Abiraterone acetate is approved … prostate cancer (CRPC). When administered in combination
with prednisone in a placebo-controlled, multinational phase III study, abiraterone acetate …

… Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate
cancer. We assessed the effect of this combination in men starting long-term androgen-…